Physician profile
James E Wallace
NPI 1639104375
$12,409.60
in general payments reported to CMS, 2019-2025
57 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,894 · 2020: $651 · 2021: $1,423 · 2022: $1,793 · 2023: $1,856 · 2024: $1,939 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,647.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,662.81 | 2019 | |
| Abbvie INC. | $1,661.52 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,322.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $885.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $574.03 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $507.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $443.93 | 2021-2025 | |
| Abbott Laboratories | $433.54 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Janssen Pharmaceuticals, INC | $426.32 | 2019-2025 | Spravato |
| Amgen INC. | $385.17 | 2019-2025 | Otezla, Repatha, Evenity |
| Lundbeck LLC | $335.92 | 2022-2025 | Vyepti, Rexulti |
| Exact Sciences Corporation | $319.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $311.19 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $251.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $221.52 | 2019-2023 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.